[Anticoagulation in patients with chronic renal failure]
- PMID: 16562602
[Anticoagulation in patients with chronic renal failure]
Abstract
Anticoagulation may be difficult to implement in patients suffering from chronic renal failure on account of platelet disorders and impaired clearance of some anticoagulant drugs. Although no adjustment of heparin and coumarin dosage is necessary, more frequent testing of coagulation pathways may be required when these drugs are used in patients with renal failure. Long-term use of LMWH should be implemented cautiously with regular testing of anti-factor Xa activity and a half-dose may be advocated in patients with a creatinine clearance < 30 ml/mn. Danaparoid and thrombin inhibitors should be used mainly in patients suffering from renal failure and heparin-induced thrombocytopenia with regular monitoring of coagulation tests.
Similar articles
-
The safety of heparins in end-stage renal disease.Semin Dial. 2006 Jul-Aug;19(4):305-10. doi: 10.1111/j.1525-139X.2006.00177.x. Semin Dial. 2006. PMID: 16893408 Review.
-
Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.Nephrol Dial Transplant. 2006 Apr;21(4):1013-8. doi: 10.1093/ndt/gfi293. Epub 2005 Dec 2. Nephrol Dial Transplant. 2006. PMID: 16326745
-
Systemic anticoagulation considerations in chronic kidney disease.Adv Chronic Kidney Dis. 2010 Sep;17(5):420-7. doi: 10.1053/j.ackd.2010.06.002. Adv Chronic Kidney Dis. 2010. PMID: 20727512 Review.
-
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.Nephrol Dial Transplant. 2003 Oct;18(10):2097-104. doi: 10.1093/ndt/gfg272. Nephrol Dial Transplant. 2003. PMID: 13679486
-
Low molecular weight heparin and bleeding in patients with chronic renal failure.Curr Opin Pulm Med. 2007 Sep;13(5):409-13. doi: 10.1097/MCP.0b013e328216430d. Curr Opin Pulm Med. 2007. PMID: 17940486 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical